Neural and Hypotensive Effects of Angiotensin II Receptor Blockade

Hypertension

Volumn 31, Issue 1, 1998, Pages 378-383

  Rongen, Gerard A ^a   Brooks, Steven C ^a   Ando, Shin ichi ^a   Dajani, Hilmi R ^a   Abramson, Beth L ^a   Floras, John S ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; PLACEBO; ANGIOTENSIN RECEPTOR; NORADRENALIN;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; NORADRENALIN RELEASE; NORMAL HUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SODIUM RESTRICTION; SUPINE POSITION; VASCULAR RESISTANCE; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; FOREARM; HEART RATE; HEMODYNAMICS; MALE; RANDOMIZATION; REFERENCE VALUE; VASCULARIZATION;

ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FOREARM; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; LOSARTAN; MALE; NOREPINEPHRINE; RANDOM ALLOCATION; RECEPTORS, ANGIOTENSIN; REFERENCE VALUES; VASCULAR RESISTANCE;

EID: 0031612863     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.378     Document Type: Article

References (32)

1. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763-E778.
2. Jeunemaitre X, Menard J, Nussberger J, Guyene T-T, Brunner HR, Corvol P. Plasma angiotesins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens. 1989;2:819-827.
3. de Gasparo M, Cumin F, Nussberger J, Guyene T-T, Wood JM, Menard J. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol. 1989:27:587-596.
4. Nussberger J, Fasanella D'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, Kler L, Brown AN, Francis RJ. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987;9:39-44.
5. Kiowski W, Linder L, Kleinbloessem CH, van Brummelen P, Buhler FR. Blood pressure control by the renin-angiotensin system in normotensive subjects; assessment by angiotensin converting enzyme and renin inhibition. Circulation. 1992;83:1-8.
6. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.
7. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 1993;22:579-584.
8. Doig JK, MacFadyen RJ, Sweet CS. Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993;21:732-738.
9. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
10. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJJ, Bjornsson TD. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
11. Doig JK, MacFadyen RJ, Sweet CS, Reid JL. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol. 1995;25:511-517.
12. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-347.
13. Lenders J, Janssen G-J, Smits P, Thien T. Role of the wrist cuff in forearm plethysmography. Clin Sci. 1991;80:413-417.
14. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol. 1996;28:155-161.
15. Ando S, Dajani H, Floras JS. Frequency domain characteristics of muscle sympathetic nerve activity in heart failure and healthy humans. Am J Physiol. 1997;273:R205-R212.
16. Grossman E, Chang PC, Hoffman A, Tamrat M, Kopin IJ, Goldstein DS. Tracer norepinephrine kinetics: dependence on regional blood flow and the site of infusion. Am J Physiol. 1991;260:R946-R952.
17. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3-20.
18. Chang PC, Kriek E, Brummelen van P. Sympathetic activity and pre-synaptic adrenoceptor function in patients with longstanding essential hypertension. J Hypertens. 1994;12:179-190.
19. Song K, Zhou J, Mendelsohn FAO. Access of peripherally administered DuP 753 to rat brain angiotensin II receptors. Br J Pharmacol. 1991;104:771-772.
20. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II antagonists. XI. Pharmacology of EXP 3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;255:211-217.
21. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet. 1997;32:1-29.
22. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, Shichiri M, Marumo F. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension. 1991;18:165-170.
23. Brunner F, Kukovetz WR. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors: role of suppression of endogenous endothelin secretion. Circulation. 1996;94:1752-1761.
24. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
25. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
26. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
27. Sudhir K, MacGregor JS, Gupta M, Barbant SD, Redberg R, Yock PG, Chatterjee K. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo: intravascular two-dimensional and Doppler ultrasound studies. Circulation. 1993;87:931-938.
28. Aiken JW, Reit E. Stimulation of the cat stellate ganglion by angiotensin. J Pharmacol Exp Ther. 1968;159:107-114.
29. Matsukawa T, Gotoh E, Minamisawa M, Kihara S, Ueda H, Shionoiri H, Ishii M. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol. 1991;R690-R696.
30. Clemson B, Gaul L, Gubin SS, Campsey DM, McConville J, Nussberger J, Zelis R. Prejunctional angiotensin II receptors; facilitation of norepinephrine release in the human forearm. J Clin Invest. 1994;93:684-691.
31. Matsukawa T, Mano T, Gotoh E, Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Invest. 1993;92:25-28.
32. Dibner-Dunlap ME, Smith ML, Kinugawa T, Thames MD. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol. 1996;27:358-364.